(NASDAQ: IRON) Disc Medicine's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.82%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Disc Medicine's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast IRON's revenue for 2026 to be $864,194,929, with the lowest IRON revenue forecast at $653,202,804, and the highest IRON revenue forecast at $1,045,955,709. On average, 5 Wall Street analysts forecast IRON's revenue for 2027 to be $3,409,746,343, with the lowest IRON revenue forecast at $342,879,521, and the highest IRON revenue forecast at $4,927,767,493.
In 2028, IRON is forecast to generate $7,751,917,175 in revenue, with the lowest revenue forecast at $3,456,502,641 and the highest revenue forecast at $11,578,937,504.